ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of biologic
therapies for life-threatening, drug-resistant infectious diseases,
today announced that Dr. Vance Fowler will present new data from
the Phase 2 study of exebacase (CF-301) at a late-breaker session
at the 29th European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) to be held from April 13-16, 2019, in
Amsterdam, Netherlands. ContraFect will also deliver an oral
presentation of novel data from its lysin program targeting
resistant Gram-negative (GN) pathogens, which demonstrate the
potential for lysins to re-sensitize carbapenem-resistant
Pseudomonas aeruginosa (P. aeruginosa) to both meropenem and
imipenem. In addition, the Company will present new data
demonstrating the potent activity of exebacase against
Staphylococcus epidermidis (Staph epidermidis) in synovial fluid.
ContraFect will also present an overview of its discovery research
programs targeting resistant GN bacteria as one of eight companies
invited to the Pipeline Talk session.
“In January of this year, we established
proof-of-concept for our first lysin candidate with positive
topline data from our Phase 2 trial of exebacase. We are pleased to
have new data from Phase 2 presented by Dr. Fowler, the Principle
Investigator of the study, at an oral late-breaking session. We are
excited to present new data showing the ability of our GN lysins to
re-sensitize carbapenem-resistant strains of P. aeruginosa to
meropenem and imipenem in vitro. In addition, we will be presenting
new data demonstrating exebacase’s potent bactericidal and
anti-biofilm activity in synovial fluid against Staph epidermidis,
an important pathogen in bone and joint infections. The activity of
exebacase in synovial fluid is highly encouraging as we consider
the potential additional applications of lysin therapeutics,” said
Cara Cassino, M.D., Chief Medical Officer and Executive Vice
President of Research and Development at ContraFect.
Presentation Details:
Presentation Title: Lysin
GN123 re-sensitizes carbapenem-resistant P. aeruginosa to
imipenemSession Day & Time: Saturday,
April 13, 2019, 1:48 p.m. – 1:53 p.m. CEST Presentation
Number: # O0200 Session
Title: Antibacterial activity of unusual
combinations
Presentation Title: Lysin exebacase (CF-301)
exhibits potent bactericidal activity in human synovial fluid
against biofilm-forming Staph epidermidis isolatesOral
Presentation Day & Time: Saturday, April 13, 2019,
3:30 p.m. – 4:30 p.m. CEST Presentation
Number: #P0528Session Title: Biofilm
eradication strategies
The Pipeline Corner: The
moderated session will feature a discussion of ContraFect’s early
R&D pipeline and presentation. Session Day &
Time: Sunday, April 14, 2019, 12:15 p.m. – 1:15 p.m.
CEST Session Title: Pipeline Talk
Presentation Title: Exebacase (Lysin CF-301)
improved clinical responder rates in methicillin-resistant
Staphylococcus aureus (MRSA) bacteremia including endocarditis
compared to standard of care antibiotics alone in a first-in
patient Phase 2 studyOral Presentation Day &
Time: Tuesday, April 16, 2019, 11:24 a.m. – 11:34 a.m.
CEST Presentation Number: #
L0012Session Title: Recent clinical trials
The abstracts can be accessed through the ECCMID website.
Following the meeting, the presentation posters will be available
on the ContraFect website.
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapies for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin platform and
through the use of other novel agents. Lysins are a new therapeutic
class of bacteriophage-derived, recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics. We believe that the
properties of our lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staphylococcus aureus
(“Staph aureus”) and P. aeruginosa, which can cause serious
infections such as bacteremia, pneumonia and osteomyelitis. Our
lead lysin candidate, exebacase (CF-301) is completing a Phase 2
clinical trial for the treatment of Staph aureus bacteremia,
including endocarditis and is the first lysin to enter clinical
studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
About Exebacase (CF-301):
Exebacase (CF-301) is a recombinantly-produced
lysin (cell wall hydrolase enzyme) with potent bactericidal
activity against Staph aureus, a major cause of blood stream
infections (BSIs) also known as bacteremia. Exebacase has the
potential to be a first-in-class treatment for Staph aureus
bacteremia. It has a novel, rapid, and specific mechanism of
bactericidal action against Staph aureus. By targeting a conserved
region of the cell wall that is vital to bacteria, resistance is
less likely to develop to exebacase. In addition, in vitro and in
vivo experiments have shown that exebacase is highly active against
biofilms which complicate Staph aureus infections. Exebacase was
licensed from The Rockefeller University and is being developed at
ContraFect.
Forward-Looking
Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding our ability to
discover and develop differentiated biological therapies for
life-threatening, drug-resistant infectious diseases, whether
presented data from the Phase 2 study of exebacase is new, whether
the data from ContraFect’s lysin program is novel and whether
lysins demonstrate the potential to re-sensitize
carbapenem-resistant P. aeruginosa to both meropenem and imipenem,
whether the data demonstrates potent activity of exebacase against
Staph epidermidis in synovial fluid, whether the Company
established proof-of-concept for its first lysin candidate and
whether the topline data from the Phase 2 trial of exebacase was
positive, our ability to address life threatening infections using
our therapeutic product candidates from our lysin platform and
through the use of other novel agents, whether lysins are a new
therapeutic class of bacteriophage-derived, recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics, whether the properties
of the Company’s lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staph aureus and P.
aeruginosa, whether exebacase has the potential to be a
first-in-class treatment for Staph aureus bacteremia, whether
exebacase is highly active against biofilms which complicate Staph
aureus infections and information provided regarding presentations.
Forward-looking statements are statements that are not historical
facts, nor assurances of future performance. Instead, they are
based on ContraFect’s current beliefs, expectations and assumptions
regarding the future of its business, future plans, strategies,
projections, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent risks, uncertainties and
changes in circumstances that are difficult to predict and many of
which are beyond ContraFect’s control, including those detailed in
ContraFect's filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in
the forward-looking statements. Important factors that could cause
actual results to differ include, among others, our ability to
develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024